News in brief: Urgent defect warning for popular CGM device;  Insulin-treated diabetes linked to higher PCI risk; New obesity guidelines needed 

Urgent defect warning for popular CGM device  AMSL Diabetes, manufacturer of Dexcom CGM Systems, have issued an urgent product defect warning alerting health professionals and patients that the chemotherapy drug hydroxyurea falsely elevates glucose readings on Dexcom Systems. The defect may result in failure to treat hypoglycaemia from missed low sensor glucose values and alerts ...

Already a member?

Login to keep reading.

© 2021 the limbic